(NASDAQ: TYRA) Tyra Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Tyra Biosciences's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast TYRA's revenue for 2027 to be $998,150,872, with the lowest TYRA revenue forecast at $959,330,940, and the highest TYRA revenue forecast at $1,036,970,805. On average, 3 Wall Street analysts forecast TYRA's revenue for 2028 to be $5,806,132,482, with the lowest TYRA revenue forecast at $3,086,450,540, and the highest TYRA revenue forecast at $9,320,506,307.
In 2029, TYRA is forecast to generate $15,897,719,644 in revenue, with the lowest revenue forecast at $7,520,963,126 and the highest revenue forecast at $28,738,449,356.